.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
McKesson
UBS
Chubb
AstraZeneca
Cipla
Cerilliant
Harvard Business School
Boehringer Ingelheim
US Army

Generated: November 17, 2017

DrugPatentWatch Database Preview

Oritavancin diphosphate - Generic Drug Details

« Back to Dashboard

What are the generic sources for oritavancin diphosphate and what is the scope of oritavancin diphosphate freedom to operate?

Oritavancin diphosphate
is the generic ingredient in one branded drug marketed by The Medicines Co and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Oritavancin diphosphate has one hundred and thirty-eight patent family members in thirty-seven countries and five supplementary protection certificates in five countries.

One supplier is listed for this compound.

Summary for oritavancin diphosphate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
The Medicines Co
ORBACTIV
oritavancin diphosphate
POWDER;IV (INFUSION)206334-001Aug 6, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
The Medicines Co
ORBACTIV
oritavancin diphosphate
POWDER;IV (INFUSION)206334-001Aug 6, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
The Medicines Co
ORBACTIV
oritavancin diphosphate
POWDER;IV (INFUSION)206334-001Aug 6, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
The Medicines Co
ORBACTIV
oritavancin diphosphate
POWDER;IV (INFUSION)206334-001Aug 6, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
The Medicines Co
ORBACTIV
oritavancin diphosphate
POWDER;IV (INFUSION)206334-001Aug 6, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
The Medicines Co
ORBACTIV
oritavancin diphosphate
POWDER;IV (INFUSION)206334-001Aug 6, 2014RXYesYes► Subscribe► Subscribe► Subscribe
The Medicines Co
ORBACTIV
oritavancin diphosphate
POWDER;IV (INFUSION)206334-001Aug 6, 2014RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: oritavancin diphosphate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
The Medicines Co
ORBACTIV
oritavancin diphosphate
POWDER;IV (INFUSION)206334-001Aug 6, 2014► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: oritavancin diphosphate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,843,889 Glycopeptide antibiotic derivatives► Subscribe
5,952,466 Reductive alkylation of glycopeptide antibiotics► Subscribe
5,977,062 Glycopeptide antibiotic derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: oritavancin diphosphate

Country Document Number Estimated Expiration
Mexico2011002249► Subscribe
HungaryS1600039► Subscribe
Canada2141106► Subscribe
Spain2204444► Subscribe
China100463917► Subscribe
Finland117095► Subscribe
European Patent Office2337575► Subscribe
Slovenia1016670► Subscribe
Poland180961► Subscribe
Peru40996► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ORITAVANCIN DIPHOSPHATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90041-7Sweden► SubscribePRODUCT NAME: ORITAVANCIN ELLER ETT FARMACEUTISKT GODTAGBART SALT DAERAV; REG. NO/DATE: EU/1/15/989 20150323
0834Netherlands► SubscribePRODUCT NAME: ORITAVANCIN; REGISTRATION NO/DATE: EU/1/15/989 20150323
2016000075Germany► SubscribePRODUCT NAME: ORITAVANCIN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/989 20150319
/2016Austria► SubscribePRODUCT NAME: ORITAVANCIN UND DESSEN PHARMAZEUTISCHE SALZE; REGISTRATION NO/DATE: EU/1/15/989 (MITTEILUNG) 20150323
2016 00044Denmark► SubscribePRODUCT NAME: ORITAVANCIN OG/ELLER FARMACEUTISKE SALTE HERAF, HERUNDER DIFOSFATSALTE; REG. NO/DATE: EU/1/15/989 20150323
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Cerilliant
Accenture
Dow
Covington
Julphar
AstraZeneca
Fuji
Harvard Business School
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot